COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole on Patients With Chronic Periodontitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00805558
Recruitment Status : Completed
First Posted : December 9, 2008
Last Update Posted : May 12, 2010
Universidad de Antioquia
Information provided by:
Facultad Nacional de Salud Publica

Brief Summary:
The purpose of this study is to assess the clinical and microbiological effectiveness of the moxifloxacin compared with the combination ciprofloxacin - metronidazole, when used as adjunctive therapy to scaling and root planning for the treatment of advanced chronic periodontitis.

Condition or disease Intervention/treatment Phase
Chronic Periodontitis Drug: moxifloxacin Drug: Ciprofloxacin plus metronidazole Phase 4

Detailed Description:
Periodontitis is an endemic inflammatory disease caused by a mixed bacterial biofilm infection that is followed by destruction of tooth supporting tissues. Standard of care consists of lifelong mechanical removal of the biofilm. However, outcome is variable. According to recent EFP and AAP reviews, adjunctive antimicrobial therapy may be beneficial.However, bearing in mind that Colombia has reported the frequent presence of Enterobacteriaceae (Klebsiella and Enterobacter) in subgingival plaque of patients with chronic periodontitis, the response to treatment may be different.The enteric have shown resistance to amoxicillin, amoxicillin / clavulanate, metronidazole and tetracycline in studies conducted in the United States, Norway, Brazil and Colombia.Although the combination ciprofloxacin metronidazole has been recommended in the dental literature are not known publications that demonstrate its effectiveness against periodontopathogens and enteric present in subgingival plaque of subjects with chronic periodontitis.On the other hand, some in vitro studies have demonstrated the effectiveness of moxifloxacin against periodontopathogens, but was not aware of any clinical trials or in vitro studies on antibiotic resistance and susceptibility to enteric isolated subgingival plaque of patients with chronic periodontitis in which employs moxifloxacin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole as Adjunctive Therapy to Mechanical Treatment of Patients With Chronic Periodontitis
Study Start Date : February 2009
Actual Primary Completion Date : December 2009
Actual Study Completion Date : April 2010

Arm Intervention/treatment
Experimental: Moxifloxacin
Scaling and root planing plus 400 mg moxifloxacin once daily for 7 days.
Drug: moxifloxacin
400 mg moxifloxacin once daily for 7 days
Other Name: Moxifloxacin hydrochloride

Active Comparator: Ciprofloxacin plus metronidazole
Scaling and root planing plus ciprofloxacin 1000 mg once daily for 7 days and metronidazole 500 mg twice daily for 7 days
Drug: Ciprofloxacin plus metronidazole
Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days
Other Names:
  • ciprofloxacino
  • metronidazole benzoato

Primary Outcome Measures :
  1. Probing Depth [ Time Frame: six months period (two measurements) ]

Secondary Outcome Measures :
  1. Subjective perception of treatment outcome, attachment gain,bleeding on probing, and full mouth plaque score. [ Time Frame: six months ]
  2. Microbial colonization dynamic [ Time Frame: six months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age and up
  • clinical and radiographic signs of severe (CAL 5 mm or more) chronic periodontitis.
  • at least 20 natural teeth in situ
  • pocket probing depths (PPDs) of ≥ 5 mm at a minimum of eight tooth sites
  • willingness to participate and to be available at all times required for participation
  • over 30% of the teeth present must have a PPDs)≥ 4 mm and insertion loss ≥ 5 mm evaluated by an experienced periodontist
  • informed consent signed by the patient

Exclusion Criteria:

  • if they (or parents or siblings) show confirmed or assumed allergies or hyper-sensitive skin reactions against moxifloxacin, ciprofloxacin (or other quinolones as listed in the "summary of product characteristics, Version Juli 2005"), metronidazole (or other 5-nitroimidazoles and ingredients of Flagyl® 400mg as listed in the "summary of product characteristics, Version Juli 2007"), systemic diseases or conditions as listed in the above mentioned "summary of product characteristics"
  • subjects who have undergone antibiotic therapy three months before the start of the study under interrogation
  • have Down's syndrome
  • known AIDS/HIV
  • regularly take systemic medication affecting the periodontal conditions, e.g. phenytoin, nifedipine, and/or steroid drugs
  • professional periodontal therapy during 6 months prior to baseline
  • require antibiotic treatment for dental appointments
  • are pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00805558

Layout table for location information
Faculta Nacional de Salud Publica Universidad de Antioquia
Medellin, Antioquia, Colombia, 057-4
Sponsors and Collaborators
Facultad Nacional de Salud Publica
Universidad de Antioquia
Layout table for investigator information
Principal Investigator: Carlos M Ardila, DDS Cand PhD Grupo Epidemiologia Universidad de Antioquia
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Carlos Martín Ardila Medina, Grupo Epidemiologia Universidad de Antioquia Identifier: NCT00805558    
Other Study ID Numbers: ARD-0001-CM
CBEIH-SIU 08-44-203
First Posted: December 9, 2008    Key Record Dates
Last Update Posted: May 12, 2010
Last Verified: October 2009
Keywords provided by Facultad Nacional de Salud Publica:
Chronic Periodontitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Periodontitis
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antiprotozoal Agents
Antiparasitic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors